在低收入国家发展腹膜透析:管理急性肾损伤与终末期肾病的合理方案
该综述讨论了在资源匮乏国家中,腹膜透析(PD)作为资源与环境效率更高的治疗方式,有望改善透析可及性,尤其惠及妇女和儿童等脆弱人群。Saving Young Lives 等项目已证明 PD 对急性肾损伤的益处,可为此后终末期肾病 PD 服务奠定基础。资源匮乏国家扩大 PD 项目面临多种挑战,若部分问题得以解决,PD 有望扩大这些国家的终末期肾病照护。
要点
- 低资源国家超过50%的ESKD患者无法获得透析。
- PD是资源与环境效率更高的治疗方式,可改善脆弱人群透析可及性。
- Saving Young Lives等项目已证明PD对AKI的益处。
核心结论
- PD是资源与环境效率更高的治疗方式,有望改善低资源国家透析可及性,尤其惠及妇女和儿童等脆弱人群。
研究设计与样本
- 复习性文章,讨论在低资源国家以腹膜透析管理急性肾损伤与终末期肾病的理由。
主要发现
- 据估计,低资源国家超过50%的终末期肾病患者无法获得透析。
- 血液透析可及时常伴随高自付支出,且很少达到国际指南推荐标准。
- 血液透析是高成本干预,对环境可持续性有显著负面影响,在资源贫乏国家尤甚。
- Saving Young Lives等项目已证明腹膜透析对急性肾损伤的益处。
临床怎么用
- 在低资源国家可先以PD服务急性肾损伤,再以此为基础发展终末期肾病PD项目。
局限性
- 资源贫乏国家扩大PD项目已证明面临多种挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is estimated that >50% of patients with end-stage kidney disease (ESKD) in low-resource countries are unable to access dialysis. When hemodialysis is available, it often has high out-of-pocket expenditure and is seldom delivered to the standard recommended by international guidelines. Hemodialysis is a high-cost intervention with significant negative effects on environmental sustainability, especially in resource-poor countries (the ones most likely to be affected by resultant climate change). This review discusses the rationale for peritoneal dialysis (PD) as a more resource and environmentally efficient treatment with the potential to improve dialysis access, especially to vulnerable populations, including women and children, in lower-resource countries. Successful initiatives such as the Saving Young Lives program have demonstrated the benefit of PD for acute kidney injury. This can then serve as a foundation for later development of PD services for end-stage kidney disease programs in these countries. Expansion of PD programs in resource-poor countries has proven to be challenging for various reasons. It is hoped that if some of these issues can be addressed, PD will be able to permit an expansion of end-stage kidney disease care in these countries.
引用
- Cullis B, McCulloch M, Finkelstein FO, et al. Development of PD in lower-income countries: a rational solution for the management of AKI and ESKD. Kidney Int. 2024. PMID: 38431214. doi:10.1016/j.kint.2023.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。